SonoSite Introduces Innovative Power Solutions for Increased Mobility and Extended Power Specialized for Emergency Medicine

SonoSite, Inc. (Nasdaq:SONO), the world leader and specialist in hand-carried and point-of-care ultrasound, announced today SonoSite® Mobile Solutions, for cordless charging and extended battery life of its ultrasound systems.

SonoSite’s PowerPort allows cordless charging of the SonoSite system when it is mounted or docked in the Universal Stand. Parking the stand on the PowerPort eliminates the need to find an electrical outlet and provides a designated station for the stand and system. SonoSite’s PowerPack triples battery life and can keep a system charged for 6 hours or more allowing clinicians the flexibility needed to see more patients on a single charge. The PowerPack is easily installed on the column of SonoSite’s Universal Stand.

SonoSite also announced its new ergonomic Universal Stands for added versatility and increased mobility. Compatible with the M-Turbo®, S Series™, NanoMaxx™1 and MicroMaxx® product lines, SonoSite’s Universal Stands are light, easy to customize with accessories, highly maneuverable in the hospital setting and easily positioned by the patient bedside or in other space-constrained areas.

Customer deliveries are expected to begin at the end of the fourth quarter 2009.

About SonoSite

SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in hand-carried ultrasound. Headquartered near Seattle, the company is represented by ten subsidiaries and a global distribution network in over 100 countries. SonoSite’s small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high performance ultrasound to the point of patient care.

Forward-looking Information and the Private Litigation Reform Act of 1995

Certain statements in this press release relating to the potential benefits of SonoSite’s future products and technology are “forward-looking statements” for the purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the opinions and estimates of our management at the time the statements are made and are subject to risks and uncertainties that could cause actual results to differ materially from those expected or implied by the forward-looking statements. These statements are not guaranties of future performance, are based on potentially inaccurate assumptions and are subject to known and unknown risks and uncertainties, including, without limitation, the risk that these products and technology will not yield the expected potential benefits, and the other factors contained in Item 1A. “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. We caution readers not to place undue reliance upon these forward-looking statements that speak only as to the date of this release. We undertake no obligation to publicly revise any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

1 Availability in the US pending FDA 510(k) clearance